Epilepsy: Emerging Drugs and Key Players

Epilepsy is a brain disorder that range from severe, life-threatening and disabling, to ones that are much more benign. In Epilepsy, the regular pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behaviour or occasionally convulsions, muscle spasms, and loss of consciousness. The cause is the abnormality in brain wiring, an imbalance of nerve signalling chemicals known as neurotransmitters, which changes the essential features of brain cells called channels, or a combination of these and other factors.

Epilepsy Market

Many companies are involved in the launch of potential therapies that may increase Epilepsy market size in the coming years. The key players such as Marinus Pharmaceuticals, Sage Therapeutics, SK Biopharmaceuticals, UCB, Neurelis, Zogenix, Aquestive Therapeutics, INSYS Therapeutics, Engage Therapeutics, Zynerba Pharma, and many others have the potential to create a significant positive shift in the Epilepsy Market Size. 

SK Biopharmaceuticals is developing a next-generation antiepileptic drug, Cenobamate (YKP3089) that exhibits broad-spectrum anticonvulsant activity. It displays superior efficacy and safety measures and will be positioned as a blockbuster leading antiepileptic drug market. It has completed Phase III stage of development for Epilepsy treatment. YKP3089 has received the US FDA permission to skip the efficacy testing stage for upcoming Phase III trials in the United States. The Company has recently submitted the NDA to the FDA for marketing approval. In February 2019, The FDA accepted a New Drug Application (NDA) from SK Life Science for cenobamate, it is an investigational antiepileptic agent for the treatment of partial-onset seizures in adult patients. This will mark a new horizon for the treatment of Epilepsy patients. 

Fintepla (ZX008) is an orally available, low-dose fenfluramine liquid solution. Zogenix is developing the drug candidate as an adjunctive treatment for Dravet syndrome. The drug has completed its Phase III studies for both the indications. It has been granted Orphan Designation in the United States, and the European Union followed by Fastrack and Breakthrough Therapy.

Marinus Pharmaceuticals is developing Ganaxolone, a synthetic analogue of allopregnanolone. It is an allosteric modulator of GABAA receptors acting through binding sites. Ganaxolone is currently being developed in three different dose forms, (IV, capsule, and liquid) intended to boost the therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. It is under development by Marinus Pharmaceuticals and is currently undergoing Phase III clinical trials for the treatment of Pediatric Refractory Epilepsy, infants with newly diagnosed infantile spasms, in women with catamenial Epilepsy, and adults with refractory partial-onset seizures. The US Food and Drug Administration has also granted Orphan Drug Designation for the treatment of Status Epilepticus and protocadherin 19 gene female pediatric epilepsy.

Apart from these, a few other key players such as Biogen and CuroNZ are also developing therapies for Epilepsy treatment. Biogen is developing natalizumab for the treatment of drug-resistant focal Epilepsy. Natalizumab is an α4-integrin inhibitor currently in the Phase II stage of development and is being investigated as adjunctive therapy in the treatment of adult patients with drug-resistant focal Epilepsy. CuroNZ began a small proof-of-concept study in Epilepsy for a cell-penetrating peptide (NRP2945) that crosses the blood-brain barrier. NRP2945 is a systemically acting injectable that is readily crossing the blood-brain barrier and being ultra-potent in providing neuroprotection, neural regeneration including synaptogenesis in the central nervous system (CNS) by working via a novel mechanism of action at plasma membrane level of CNS neurons.   

In conclusion, many biopharmaceutical companies are developing drugs to combat the disease that help in fuelling the Epilepsy market and will have a rise in market size.

Click here to view full report: https://www.delveinsight.com/report-store/epilepsy-market